Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

Objectives To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase 3b COSMOS trial. Subgroups were defined by bas...

Full description

Saved in:
Bibliographic Details
Main Authors: Iain B McInnes, Laura C Coates, Philipp Sewerin, Frédéric Lavie, Mohamed Sharaf, Miriam Zimmermann, Michela Efficace
Format: Article
Language:English
Published: BMJ Publishing Group 2024-12-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/10/4/e004494.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items